HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2006.12.049v1 49/23/2249    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fox, K. A.A. Articles by Braunwald, E. Search for Related Content PubMed Articles by Fox, K. A.A. Articles by Braunwald, E.

FOCUS ISSUE: EXTRACT–TIMI 25 TRIAL

The Impact of Renal Dysfunction on Outcomes in the ExTRACT-TIMI 25 Trial

Keith A.A. Fox, FRCP^_*, Elliott M. Antman, MD, FACC^,_*, Gilles Montalescot, MD, Stefan Agewall, MD, Bhupathi SomaRaju, MD^||, Freek W.A. Verheugt, MD, FACC^¶, Jose Lopez-Sendon, MD, FACC^#, Hanoch Hod, MD, FACC^_**, Sabina A. Murphy, MPH and Eugene Braunwald, MD, MACC

^_* University of Edinburgh, Edinburgh, United Kingdom
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
Institut de Cardiologie, Pitie-Salpetriere University Hospital, Paris, France
Coronary Care Unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden
^|| CARE Hospital, Hyderabad, India
^¶ University Hospital Nijmegen, Nijmegen, the Netherlands
^# Hospital Universitario La Paz Madrid, Madrid, Spain
^_** Heart Institute, Sheba Medical Center, Tel Hashomer, Israel

Manuscript received September 7, 2006; revised manuscript received December 5, 2006, accepted December 10, 2006.

^_* Reprint requests and correspondence: Dr. Elliott M. Antman, TIMI Study Group, 350 Longwood Avenue, First Floor, Boston, Massachusetts 02115. (Email: eantman{at}rics.bwh.harvard.edu).

Objectives: The ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment–Thrombolysis In Myocardial Infarction 25) trial provided the opportunity to evaluate the impact of renal dysfunction on outcomes in patients with ST-segment elevation myocardial infarction (STEMI) and compare enoxaparin (ENOX) and unfractionated heparin (UFH).

Background: It is unclear how renal dysfunction influences the balance between benefit and risk of antithrombotic therapy.

Methods: In the ExTRACT-TIMI 25 trial, 20,479 patients were randomized to UFH or ENOX. A reduced ENOX dose was administered to patients age 75 years and those with an estimated creatinine clearance (CrCl) <30 ml/min.

Results: A powerful relationship was observed between the severity of renal dysfunction (per 10 ml/min decrement in CrCl) and death, stroke, intracranial hemorrhage, and major and minor bleeding (p < 0.001 for each). There was a progressive increase in the treatment benefit with ENOX on death or nonfatal myocardial infarction (p < 0.01) with better renal function. Net clinical benefit (death, nonfatal MI, or nonfatal major bleeding) was significantly superior with ENOX (p < 0.001) for patients with a CrCl >60 ml/min (79.1% of the study population). Major bleeding and intracranial hemorrhage did not differ for patients with preserved renal function (CrCl >90 ml/min), but in those with renal dysfunction there was a progressively greater increase in the risk of major and minor bleeding with ENOX.

Conclusions: Enoxaparin was superior to UFH for the majority of subjects. With more severe renal dysfunction, the net clinical benefit between ENOX and UFH did not differ, despite the rise in adverse events in both treatment groups. Future studies should take renal dysfunction into account when assessing antithrombotic regimens.

Abbreviations and Acronyms   CI = confidence interval   CrCl = creatinine clearance   ENOX = enoxaparin   LMWH = low-molecular-weight heparin   MI = myocardial infarction   ORadj = adjusted odds ratio   STEMI = ST-segment elevation myocardial infarction   UFH = unfractionated heparin

This article has been cited by other articles:

				R. Dumaine, M. Borentain, O. Bertel, C. Bode, R. Gallo, H. D. White, J.-P. Collet, S. R. Steinhubl, and G. Montalescot Intravenous Low-Molecular-Weight Heparins Compared With Unfractionated Heparin in Percutaneous Coronary Intervention: Quantitative Review of Randomized Trials Arch Intern Med, December 10, 2007; 167(22): 2423 - 2430. [Abstract] [Full Text] [PDF]